Business Context and Reporting Period
This Form 8-K Current Report was filed by Kiora Pharmaceuticals, Inc. (Nasdaq: KPRX) on April 21, 2022. The report discloses a material change in executive leadership, specifically the appointment of an Interim Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and related contractual terms.
Material Changes
- Executive Appointment: On April 21, 2022, the Board of Directors appointed Susan L. Drexler as Interim Chief Financial Officer, effective immediately.
- Roles: Ms. Drexler will also serve as the Company's principal accounting officer and principal financial officer.
- Compensation Structure: Ms. Drexler provides services as an independent contractor and employee of Danforth Advisors, LLC. Danforth receives cash compensation at a rate of $450 per hour for her services.
- Contract Terms: The Consulting Agreement may be terminated with cause upon 30 days' notice or without cause upon 60 days' notice.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. No specific risks or contingencies are disclosed in this report other than the standard contractual termination provisions.
Investor Verification Checklist
- Verify the full terms of the Consulting Agreement filed as Exhibit 10.1.
- Confirm the transition timeline for the previous Chief Financial Officer.
- Review subsequent filings for any updates to the interim CFO status or permanent appointment.
- Check the Company's most recent 10-Q or 10-K for current liquidity and cash runway, as this 8-K does not contain financial data.